000863338 001__ 863338
000863338 005__ 20220930130213.0
000863338 0247_ $$2doi$$a10.3390/molecules24122237
000863338 0247_ $$2Handle$$a2128/22716
000863338 0247_ $$2altmetric$$aaltmetric:62276821
000863338 0247_ $$2pmid$$apmid:31208037
000863338 0247_ $$2WOS$$aWOS:000473816900043
000863338 037__ $$aFZJ-2019-03418
000863338 082__ $$a540
000863338 1001_ $$0P:(DE-Juel1)132029$$aWillbold, Dieter$$b0$$eCorresponding author
000863338 245__ $$aDo We Need Anti-Prion Compounds to Treat Alzheimer’s Disease?
000863338 260__ $$aBasel$$bMDPI75390$$c2019
000863338 3367_ $$2DRIVER$$aarticle
000863338 3367_ $$2DataCite$$aOutput Types/Journal article
000863338 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1568036347_22203
000863338 3367_ $$2BibTeX$$aARTICLE
000863338 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000863338 3367_ $$00$$2EndNote$$aJournal Article
000863338 520__ $$aWhile phase III clinical trials for the treatment of Alzheimer’s disease (AD) keep failing regardless of the target, more and more data suggest that the toxic protein assemblies of amyloid-beta protein (Aβ) and tubulin binding protein (TAU) behave like prions. Irrespective of the question of whether AD is theoretically or practically contagious, the presence of a self-replicating toxic etiologic agent in the brains of AD patients must have decisive consequences for drug development programs and clinical trial designs. Objectives: We intend to challenge the hypothesis that the underlying etiologic agent of AD is behaving prion-like. We want to discuss whether the outcome of clinical trials could have been predicted based on this hypothesis, and whether compounds that directly disassemble the toxic prion could be more beneficial for AD treatment. Method: We collected publicly accessible pre-clinical efficacy data of Aβ targeting compounds that failed or still are in phase III clinical trials. We describe the desired properties of an anti-prion compound and compare it the properties of past and current phase III drug candidates. Results: We could not find convincing and reproducible pre-clinical efficacy data of past and current phase III drug candidates on cognition other than in preventive treatment settings. The desired properties of an anti-Aβ-prionic compound are fulfilled by the drug candidate RD2, which has been developed to directly disassemble toxic Aβ oligomers. Conclusion: RD2 is the first anti-prion drug candidate. It is able to enhance cognition and impede neurodegeneration in three different transgenic AD mouse models, even under truly non-preventive conditions and even when applied orally. In addition, it is safe in humans.
000863338 536__ $$0G:(DE-HGF)POF3-553$$a553 - Physical Basis of Diseases (POF3-553)$$cPOF3-553$$fPOF III$$x0
000863338 588__ $$aDataset connected to CrossRef
000863338 7001_ $$0P:(DE-Juel1)159137$$aKutzsche, Janine$$b1
000863338 773__ $$0PERI:(DE-600)2008644-1$$a10.3390/molecules24122237$$gVol. 24, no. 12, p. 2237 -$$n12$$p2237 -$$tMolecules$$v24$$x1420-3049$$y2019
000863338 8564_ $$uhttps://juser.fz-juelich.de/record/863338/files/Invoice_MDPI_molecules-521175.pdf
000863338 8564_ $$uhttps://juser.fz-juelich.de/record/863338/files/Invoice_MDPI_molecules-521175.pdf?subformat=pdfa$$xpdfa
000863338 8564_ $$uhttps://juser.fz-juelich.de/record/863338/files/molecules-24-02237.pdf$$yOpenAccess
000863338 8564_ $$uhttps://juser.fz-juelich.de/record/863338/files/molecules-24-02237.pdf?subformat=pdfa$$xpdfa$$yOpenAccess
000863338 8767_ $$8molecules-521175$$92019-06-13$$d2019-07-01$$eAPC$$jZahlung erfolgt
000863338 909CO $$ooai:juser.fz-juelich.de:863338$$popenCost$$pVDB$$pdriver$$pOpenAPC$$popen_access$$popenaire$$pdnbdelivery
000863338 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)132029$$aForschungszentrum Jülich$$b0$$kFZJ
000863338 9101_ $$0I:(DE-588b)5008462-8$$6P:(DE-Juel1)159137$$aForschungszentrum Jülich$$b1$$kFZJ
000863338 9131_ $$0G:(DE-HGF)POF3-553$$1G:(DE-HGF)POF3-550$$2G:(DE-HGF)POF3-500$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bKey Technologies$$lBioSoft – Fundamentals for future Technologies in the fields of Soft Matter and Life Sciences$$vPhysical Basis of Diseases$$x0
000863338 9141_ $$y2019
000863338 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000863338 915__ $$0LIC:(DE-HGF)CCBY4$$2HGFVOC$$aCreative Commons Attribution CC BY 4.0
000863338 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000863338 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bMOLECULES : 2017
000863338 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000863338 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000863338 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000863338 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000863338 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000863338 915__ $$0StatID:(DE-HGF)0510$$2StatID$$aOpenAccess
000863338 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000863338 915__ $$0StatID:(DE-HGF)1150$$2StatID$$aDBCoverage$$bCurrent Contents - Physical, Chemical and Earth Sciences
000863338 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000863338 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000863338 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000863338 9201_ $$0I:(DE-Juel1)ICS-6-20110106$$kICS-6$$lStrukturbiochemie$$x0
000863338 9801_ $$aAPC
000863338 9801_ $$aFullTexts
000863338 980__ $$ajournal
000863338 980__ $$aVDB
000863338 980__ $$aUNRESTRICTED
000863338 980__ $$aI:(DE-Juel1)ICS-6-20110106
000863338 980__ $$aAPC
000863338 981__ $$aI:(DE-Juel1)IBI-7-20200312